Skip to main content
OSTI.GOVU.S. Department of Energy Office of Scientific and Technical Information
U.S. Department of Energy
Office of Scientific and Technical Information
 

Hyperfractionated radiotherapy with or without misonidazole: results of a prospective randomized study in stage III-IV squamous cell carcinoma of the head and neck

Journal Article · · Int. J. Radiat. Oncol., Biol. Phys.; (United States)
; ; ;

From 1979 to 1980, 52 patients with Stage III-IV squamous cell carcinoma of the head and neck were included in a prospective randomized study on hyperfractionated radiotherapy with or without misonidazole. The radiotherapeutic schedule consisted of two weeks of treatment split by a rest-period of one month, 6 x 1.1 Gy fractions per day for 5 consecutive days. Total dose of misonidazole was 12 g/m2 administered daily in 1.2 g/m2 fractions. The overall tolerance of misonidazole was good, with a neuropathy rate of 5.7%. Local control, recurrence and 3 year survival rates did not statistically differ between the two groups. The randomized trials published at the present time, including or own, suggest that misonidazole has no beneficial effect with classical, concentrated or multiple fractions per day radiotherapy.

Research Organization:
Institut Jean Godinot, Reims, France
OSTI ID:
6302519
Journal Information:
Int. J. Radiat. Oncol., Biol. Phys.; (United States), Journal Name: Int. J. Radiat. Oncol., Biol. Phys.; (United States) Vol. 10:10; ISSN IOBPD
Country of Publication:
United States
Language:
English

Similar Records

Hyperfractionated radiotherapy in advanced squamous cell carcinoma of the head and neck
Journal Article · Mon Feb 28 23:00:00 EST 1983 · Int. J. Radiat. Oncol., Biol. Phys.; (United States) · OSTI ID:5651956
Misonidazole combined with radiotherapy in the treatment of inoperable squamous cell carcinoma of the lung. A double-blind randomized trial
Journal Article · Fri Jul 01 00:00:00 EDT 1983 · Cancer (Philadelphia); (United States) · OSTI ID:5296711
Failure of misonidazole-sensitized radiotherapy to impact upon outcome among stage III-IV squamous cancers of the head and neck
Journal Article · Sat Aug 01 00:00:00 EDT 1987 · Int. J. Radiat. Oncol., Biol. Phys.; (United States) · OSTI ID:6020843

Related Subjects

550603 -- Medicine-- External Radiation in Therapy-- (1980-)
560151* -- Radiation Effects on Animals-- Man
62 RADIOLOGY AND NUCLEAR MEDICINE
63 RADIATION, THERMAL, AND OTHER ENVIRON. POLLUTANT EFFECTS ON LIVING ORGS. AND BIOL. MAT.
ANTINEOPLASTIC DRUGS
AZOLES
BIOLOGICAL EFFECTS
BIOLOGICAL RADIATION EFFECTS
BODY
BODY AREAS
CARCINOMAS
DISEASES
DRUGS
FRACTIONATED IRRADIATION
HEAD
HETEROCYCLIC COMPOUNDS
IMIDAZOLES
IRRADIATION
MEDICINE
MISONIDAZOLE
NECK
NEOPLASMS
NERVOUS SYSTEM
NUCLEAR MEDICINE
ORGANIC COMPOUNDS
ORGANIC NITROGEN COMPOUNDS
PATIENTS
RADIATION EFFECTS
RADIOLOGY
RADIOSENSITIVITY EFFECTS
RADIOSENSITIZERS
RADIOTHERAPY
SIDE EFFECTS
THERAPY